The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin

Gynecological Endocrinology

Volumn 30, Issue 6, 2014, Pages 444-450

  Arce, Joan Carles ^a   Klein, Bjarke M ^a   La Marca, Antonio ^b  

^a Ferring Pharmaceuticals AS   (Denmark)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

GnRH agonist; GnRH antagonist; Gonadotropins; Live birth; Ovarian response

Indexed keywords

ESTRADIOL; FOLLITROPIN; GANIRELIX; HUMAN MENOPAUSAL GONADOTROPIN; MUELLERIAN INHIBITING FACTOR; PROGESTERONE; RECOMBINANT FOLLITROPIN; TRIPTORELIN; BIOLOGICAL MARKER; FERTILITY PROMOTING AGENT; GONADORELIN; RECOMBINANT PROTEIN;

ADULT; ANTRAL FOLLICLE COUNT; ARTICLE; BLASTOCYST; BODY MASS; CONTROLLED STUDY; EMBRYO; EMBRYO TRANSFER; FEMALE; FEMALE GENITAL TRACT PARAMETERS; FERTILIZATION IN VITRO; HORMONE BLOOD LEVEL; HUMAN; INFERTILITY THERAPY; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; MAJOR CLINICAL STUDY; OOCYTE; OOCYTE RETRIEVAL; OVARIAN RESPONSE; OVARIAN STIMULATION; OVARY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TREATMENT RESPONSE; AGONISTS; ANTAGONISTS AND INHIBITORS; BLOOD; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; INFERTILITY, FEMALE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PATHOPHYSIOLOGY; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; RISK; SECRETION (PROCESS); UPREGULATION;

ADULT; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; EMBRYO TRANSFER; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE, HUMAN; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; LIVE BIRTH; MENOTROPINS; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; OVULATION INDUCTION; PREGNANCY; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK; SPERM INJECTIONS, INTRACYTOPLASMIC; UP-REGULATION;

EID: 84901259505     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2014.892066     Document Type: Article

References (55)

1. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: From theory to practice. Hum Reprod Update 2014;20:124-40
2. Devroey P, Polyzos NP, Blockeel C. An OHSS-free clinic by segmentation of IVF treatment. Hum Reprod 2011;26:2593-7
3. Pu D, Wu J, Liu J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. Hum Reprod 2011;26:2742-9
4. Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y. Meta-Analysis of GnRH antagonist protocols: Do they reduce the risk of OHSS in PCOS? Reprod Biomed Online 2012;24:6-22
5. Kol S, Homburg R, Alsbjerg B, Humaidan P. The gonadotropinreleasing hormone antagonist protocol-The protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation. Acta Obstet Gynecol Scand 2012;91:643-7
6. Van Der Gaast MH, Eijkemans MJ, Van Der Net JB, et al. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod Biomed Online 2006;13:476-80. (Pubitemid 44548781
7. Sunkara SK, Rittenberg V, Raine-Fenning N, et al. Association between the number of eggs and live birth in IVF treatment: An analysis of 400 135 treatment cycles. Hum Reprod 2011;26: 1768-74
8. Kok JD, Looman CW, Weima SM, Te Velde ER. A high number of oocytes obtained after ovarian hyperstimulation for in vitro fertilization or intracytoplasmic sperm injection is not associated with decreased pregnancy outcome. Fertil Steril 2006;85:918-24
9. Fatemi HM, Doody K, Griesinger G, et al. High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-Antagonist protocol. Hum Reprod 2013;28:442-52
10. Nelson SM, Yates RW, Lyall H, et al. Anti-Müllerian hormonebased approach to controlled ovarian stimulation for assisted conception. Hum Reprod 2009;24:867-75
11. Yates AP, Rustamov O, Roberts SA, et al. Anti-Mullerian hormonetailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum Reprod 2011;26:2353-62
12. Nyboe Andersen A, Devroey P, Arce J-C; for the MERIT Group. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: A randomized assessor-blind controlled trial. Hum Reprod 2006;21:3217-27
13. Devroey P, Pellicer A, Nyboe Andersen A, Arce J-C; on behalf of the Menopur in GnRH Antagonist Cycles with Single Embryo Transfer (MEGASET) Trial Group. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril 2012;97:561-71
14. Wolfenson C, Groisman J, Couto AS, et al. Batch-To-batch consistency of human-Derived gonadotrophin preparations compared with recombinant preparations. Reprod Biomed Online 2005;10: 442-54. (Pubitemid 40485002
15. La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010;16:113-30
16. La Marca A, Giulini S, Tirelli A, et al. Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007;22:766-71
17. Nelson SM, Yates RW, Fleming R. Serum anti-Müllerian hormone and FSH: Prediction of live birth and extremes of response in stimulated cycles-implications for individualization of therapy. Hum Reprod 2007;22:2414-21. (Pubitemid 47289055
18. Lee TH, Liu CH, Huang CC, et al. Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod 2008;23:160-7
19. Nardo LG, Gelbaya TA, Wilkinson H, et al. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 2009;92:1586-93
20. Broer SL, Dólleman M, Opmeer BC, et al. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: A meta-Analysis. Hum Reprod Update 2011;17:46-54
21. Anckaert E, Smitz J, Schiettecatte J, et al. The value of anti-Müllerian hormone measurement in the long GnRH agonist protocol: Association with ovarian response, dose adjustments, embryo quality and pregnancy. Hum Reprod 2012;27:1829-39
22. Arce J-C, La Marca A, Mirner Klein B, et al. Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: Prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril 2013;99:1644-53
23. Gardner DK, Schoolcraft WB. In-vitro culture of human blastocysts. In: Jansen R, Mortimer D, eds. Towards reproductive certainty: Fertility and genetics beyond 1999. New York: The Parthenon Publishing Group; 1999:378-88
24. Kolibianakis EM, Collins J, Tarlatzis BC, et al. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-Analysis. Hum Reprod Update 2006; 12:651-71. (Pubitemid 44605507
25. Al-Inany HG, Youssef MA, Aboulghar M, et al. Gonadotrophinreleasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011;5:CD001750
26. Fleming R, Broekmans F, Calhaz-Jorge C, et al. Can anti-Müllerian hormone concentrations be used to determine gonadotrophin dose and treatment protocol for ovarian stimulatioñ Reprod Biomed Online 2013;26:431-9
27. Nelson SM. Biomarkers of ovarian response: Current and future applications. Fertil Steril 2013;99:963-9
28. Horsman G, Talbot JA, McLoughlin JD, et al. A biological, immunological and physico-chemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon. Hum Reprod 2000;15:1898-902
29. Flack MR, Bennet AP, Froehlich J, et al. Increased biological activity due to basic isoforms in recombinant human follicle-stimulating hormone produced in a human cell line. J Clin Endocrinol Metab 1994;79:756-60. (Pubitemid 24286398
30. Barrios-De-Tomasi J, Timossi C, Merchant H, et al. Assessment of the in vitro biological activities of the human follicle stimulating hormones. Mol Cell Endocrinol 2002;186:189-98. (Pubitemid 34233713
31. Ulloa-Aguirre A, Timossi C, Barrios-De-Tomasi J, et al. Impact of carbohydrate heterogeneity in function of follicle-stimulating hormone: Studies derived from in vitro and in vivo models. Biol Reprod 2003;69:379-89. (Pubitemid 36885939
32. Lambert A, Rodgers M, Mitchell R, et al. In-vitro biopotency and glycoform distribution of recombinant human FSH (ORG32489), Metrodin and Metrodin-HP. Hum Reprod 1995;10:1928-35
33. de Leeuw R, Mulders J, Voortman G, et al. Structure-function relationship of recombinant follicle stimulating hormone (Puregon). Mol Hum Reprod 1996;2:361-9. (Pubitemid 126717451
34. Steelman SL, Pohley FM. Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotropin. Endocrinology 1953;53:604-16
35. Smitz J, Andersen AN, Devroey P, Arce J-C; MERIT Group. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod 2007;22:676-87
36. Luo W, Wiltbank MC. Distinct regulation by steroids of messenger RNAs for FSHR and CYP19A1 in bovine granulosa cells. Biol Reprod 2006;75:217-25. (Pubitemid 44107191
37. Bosch E, Labarta E, Crespo J, et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: Analysis of over 4000 cycles. Hum Reprod 2010;25:2092-100
38. Kolibianakis EM, Venetis CA, Bontis J, Tarlatzis BC. Significantly lower pregnancy rates in the presence of progesterone elevation in patients treated with GnRH antagonists and gonadotrophins: A systematic review and meta-Analysis. Curr Pharm Biotechnol 2012; 13:464-70
39. Huang R, Fang C, Xu S, et al. Premature progesterone rise negatively correlated with live birth rate in IVF cycles with GnRH agonist: An analysis of 2,566 cycles. Fertil Steril 2012;98:664-70
40. Ochsenkühn R, Arzberger A, von Schönfeldt V, et al. Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted reproductive technology: A retrospective study with 2,555 fresh embryo transfers. Fertil Steril 2012;98:347-54
41. Labarta E, Martínez-Conejero JA, Alamá P, et al. Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: A functional genomics analysis. Hum Reprod 2011;26:1813-25
42. Van Vaerenbergh I, Fatemi HM, Blockeel C, et al. Progesterone rise on HCG day in GnRH antagonist/rFSH stimulated cycles affects endometrial gene expression. Reprod Biomed Online 2011;22: 263-71
43. Melo MA, Meseguer M, Garrido N, et al. The significance of premature luteinization in an oocyte-Donation programme. Hum Reprod 2006;21:1503-07. (Pubitemid 44445028
44. Lahoud R, Kwik M, Ryan J, et al. Elevated progesterone in GnRH agonist down regulated in vitro fertilisation (IVFICSI) cycles reduces live birth rates but not embryo quality. Arch Gynecol Obstet 2012;285:535-40
45. Xu B, Li Z, Zhang H, et al. Serum progesterone level effects on the outcome of in vitro fertilization in patients with different ovarian response: An analysis of more than 10,000 cycles. Fertil Steril 2012; 97:1321-7
46. Younis JS, Haddad S, Matilsky M, Ben-Ami M. Premature luteinization: Could it be an early manifestation of low ovarian reserve? Fertil Steril 1998;69:461-5
47. Elgindy EA. Progesterone level and progesterone/estradiol ratio on the day of hCG administration: Detrimental cutoff levels and new treatment strategy. Fertil Steril 2011;95:1639-44
48. Cetinkaya ES, Berker B, Aytac R, et al. The value of the progesterone-To-estradiol ratio on the day of hCG administration in predicting ongoing pregnancy and live birth rates in normoresponders undergoing GnRH antagonist cycles. Eur J Obstet Gynecol Reprod Biol 2013;170:452-7
49. Munne S, Magli C, Adler A, et al. Treatment-related chromosome abnormalities in human embryos. Hum Reprod 1997;12:780-4. (Pubitemid 27223047
50. Munné S, Ary J, Zouves C, et al. Wide range of chromosome abnormalities in the embryos of young egg donors. Reprod Biomed Online 2006;12:340-6
51. Haaf T, Hahn A, Lambrecht A, et al. A high oocyte yield for intracytoplasmic sperm injection treatment is associated with an increased chromosome error rate. Fertil Steril 2009;91:733-8
52. Rubio C, Mercader A, Alamá P, et al. Prospective cohort study in high responder oocyte donors using two hormonal stimulation protocols: Impact on embryo aneuploidy and development. Hum Reprod 2010;25:2290-7
53. Soares SR, Rubio C, Rodrigo L, et al. High frequency of chromosomal abnormalities in embryos obtained from oocyte donation cycles. Fertil Steril 2003;80:656-7. (Pubitemid 37102888
54. Ziebe S, Lundin K, Janssens R, Helmgaard L, Arce J-C; MERIT (Menotrophin vs Recombinant FSH in vitro Fertilisation Trial) Group. Influence of ovarian stimulation with HP-hMG or recombinant FSH on embryo quality parameters in patients undergoing IVF. Hum Reprod 2007;22:2404-13
55. Weghofer A, Munné S, Brannath W, et al. The impact of LH-containing gonadotropins on diploidy rates in preimplantation embryos: Long protocol stimulation. Hum Reprod 2008;23:499-503. (Pubitemid 351651217